RR-MS patients with stable disease stage showed decreased frequencies of CD14+HLA-DRlow monocytic MDSCs and CD15+CD11b+HLA-DRlow granulocytic MDSCs compared to those during relapse (23). This evidence concerns the gene ITGAM and myeloid sarcoma.